Cross-Sectional Study of Varicella Zoster Virus Immunity in Healthy Korean Children Assessed by Glycoprotein Enzyme-Linked Immunosorbent Assay and Fluorescent Antibody to Membrane Antigen Test
- PMID: 34065863
- PMCID: PMC8151998
- DOI: 10.3390/vaccines9050492
Cross-Sectional Study of Varicella Zoster Virus Immunity in Healthy Korean Children Assessed by Glycoprotein Enzyme-Linked Immunosorbent Assay and Fluorescent Antibody to Membrane Antigen Test
Abstract
The prevalence of varicella is especially high among children in the age group of 4-6 years in South Korea, regardless of vaccination. We investigated the immune status of healthy children enrolled in day-care centers and compared pre- and post-vaccination immunity. Antibody titers were measured using a glycoprotein enzyme-linked immunosorbent assay (gpEIA) kit, and the seroconversion rate was assessed using a fluorescent antibody to membrane antigen (FAMA) test. Among 541 vaccinated children, 109 (20.1%) had breakthrough varicella. However, 13 (72.2%) of the 18 unvaccinated children had a history of varicella. The gpEIA geometric mean titers (GMTs) of pre- and 5 weeks post-vaccination in 1-year-old children were 14.7 and 72 mIU/mL, respectively, and the FAMA seroconversion rate was 91.1%. The gpEIA GMTs of 2-, 3-, 4-, 5-, and 6-year-old children were 104.1, 133.8, 223.5, 364.1, and 353.0 mIU/mL, respectively. Even though the gpEIA GMT increased with age, the pattern of gpEIA titer distribution in 4- to 6-year-old vaccinees without varicella history represented both waning immunity and natural boosting immunity. These results suggest that some vaccinees are vulnerable to varicella infection. Therefore, it is necessary to consider a two-dose varicella vaccine regimen in South Korea.
Keywords: ELISA; FAMA; glycoprotein; immunity; vaccine; varicella.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Seroepidemiologic survey of varicella-zoster virus in korean adults using glycoprotein enzyme immuno assay and fluorescent antibody to membrane antigen test.Ann Dermatol. 2011 Feb;23(1):39-43. doi: 10.5021/ad.2011.23.1.39. Epub 2011 Feb 28. Ann Dermatol. 2011. PMID: 21738361 Free PMC article.
-
Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.Yonsei Med J. 2014 Mar;55(2):459-66. doi: 10.3349/ymj.2014.55.2.459. Yonsei Med J. 2014. PMID: 24532518 Free PMC article.
-
The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.Epidemiol Infect. 2016 Aug;144(11):2345-53. doi: 10.1017/S0950268816000595. Epub 2016 Mar 28. Epidemiol Infect. 2016. PMID: 27018820 Free PMC article.
-
Epidemiologic effects of varicella vaccination.Infect Dis Clin North Am. 1996 Sep;10(3):631-55. doi: 10.1016/s0891-5520(05)70318-4. Infect Dis Clin North Am. 1996. PMID: 8856357 Review.
-
Development of varicella vaccine in Japan and future prospects.Vaccine. 2016 Jun 17;34(29):3427-33. doi: 10.1016/j.vaccine.2016.04.059. Epub 2016 May 7. Vaccine. 2016. PMID: 27160039 Review.
Cited by
-
Evaluation of flow cytometry-based fluorescent antibody to membrane antigen test to measure the humoral immunity against the varicella-zoster virus.Heliyon. 2024 Aug 22;10(16):e36614. doi: 10.1016/j.heliyon.2024.e36614. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39262946 Free PMC article.
-
Seroprevalence of Varicella-Zoster Virus and Measles among Healthcare Workers in a Tertiary Medical Center in Korea.Vaccines (Basel). 2022 Nov 18;10(11):1956. doi: 10.3390/vaccines10111956. Vaccines (Basel). 2022. PMID: 36423051 Free PMC article.
-
Comparison of ELISA Versus FAMA Titers in Children After Chemotherapy and Hematopoietic Stem Cell Transplantation Who Received the Live Attenuated MAV/06 Strain Varicella Vaccine.Vaccines (Basel). 2024 Dec 5;12(12):1371. doi: 10.3390/vaccines12121371. Vaccines (Basel). 2024. PMID: 39772033 Free PMC article.
-
Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella-zoster virus.Hum Vaccin Immunother. 2023 Dec 31;19(1):2210961. doi: 10.1080/21645515.2023.2210961. Epub 2023 May 23. Hum Vaccin Immunother. 2023. PMID: 37218543 Free PMC article.
References
-
- Lee H. Survey on Efficacy and Safety of Varicella Vaccine as a Regular Vaccine in Korea. [(accessed on 5 April 2021)];2005 Volume 139 Available online: https://scienceon.kisti.re.kr/srch/selectPORSrchReport.do?cn=TRKO2013000....
Grants and funding
LinkOut - more resources
Full Text Sources